GlassScriptPhysician profile
Matthew Kahmann
NPI 1245018985
$1,029.30
in general payments reported to CMS, 2019-2025
15 companies · $801 in 2025
The $801 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $12.01 · 2024: $216 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,029.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $231.77 | 2023-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $191.88 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $137.20 | 2024-2025 | Verquvo |
| Amgen INC. | $109.83 | 2024-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $62.92 | 2025 | Nexletol |
| Cleerly, INC. | $61.29 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Pfizer INC. | $47.23 | 2025 | |
| Kestra Medical Technology Services, INC. | $46.84 | 2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.46 | 2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $19.98 | 2024 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $19.80 | 2025 | Eliquis |
| Medtronic, INC. | $18.41 | 2025 | Linq II |
| Astrazeneca Pharmaceuticals LP | $17.59 | 2025 | |
| Glaxosmithkline, LLC. | $16.37 | 2025 | Arexvy |
| Philips North America LLC | $14.73 | 2025 | Ecc Solutions |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Kahmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.